Related Experiment Video
Updated: Jul 30, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment
Marco Boeri1, Jessie Sutphin2, Brett Hauber2,3
1RTI Health Solutions, Belfast, UK.
The Journal of Dermatological Treatment
|October 7, 2020
Summary
Patients with atopic dermatitis prioritize malignancy risk and efficacy when choosing systemic treatments. They prefer oral daily medications and accept some risks for better outcomes.
Area of Science:
- Dermatology
- Health Economics
- Patient-Reported Outcomes
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition.
- Systemic treatments for moderate-to-severe AD require careful consideration of patient preferences.
- Understanding patient priorities is crucial for effective treatment selection.
Purpose of the Study:
- To identify key attributes of systemic atopic dermatitis treatments.
- To quantify patient preferences for these treatment attributes.
- To inform shared decision-making in AD management.
Main Methods:
- Qualitative interviews with 21 adults with moderate-to-severe AD.
- Online discrete-choice experiment (DCE) survey with 320 US patients.
- Random-parameters logit model for preference analysis.
Main Results:
- Malignancy risk was the most important attribute, followed by administration mode, efficacy (clear skin), and speed of itch relief.
- Patients preferred daily oral treatments over injectables.
- Increased risk of adverse events was acceptable for improved efficacy and administration.
Conclusions:
- Patient preferences significantly influence choices for systemic AD treatments.
- Risk of malignancy is a primary concern for patients.
- Findings support patient-centered care in managing moderate-to-severe AD.
